ArticleScientific reports2017
A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer.
Gwendlyn Kollmorgen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papercites it
ArticleScientific reports2017
Gwendlyn Kollmorgen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.